Roivant Sciences Ltd. (NASDAQ:ROIV), a next-generation biopharmaceutical company dedicated to improving the delivery of healthcare to patients, announced today the commencement of a proposed underwritten public offering of $150,000,000 of common shares. Roivant expects to grant the underwriter a 30-day option to purchase up to $22.5 million of additional common shares. The offering is subject to market conditions and other factors, and there can be no assurance as to whether or when the offering may be completed, or as to the actual size or terms of the offering.
Silvergate Capital Q3 EPS $1.28 Misses $1.34 Estimate, Sales $89.34M Miss $100.35M Estimate
Silvergate Capital (NYSE:SI) reported quarterly earnings of $1.28 per share which missed the analyst consensus estimate of $1.34 by 4.48 percent. This is a 45.45 percent increase over earnings of $0.88 per share from the
